Targeting HER2 expression in cancer: New drugs and new indications
نویسندگان
چکیده
منابع مشابه
CCR New Strategies New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combina...
متن کاملNew drugs targeting Th2 lymphocytes in asthma
Asthma represents a profound worldwide public health problem. The most effective anti-asthmatic drugs currently available include inhaled beta2-agonists and glucocorticoids and control asthma in about 90-95% of patients. The current asthma therapies are not cures and symptoms return soon after treatment is stopped even after long term therapy. Although glucocorticoids are highly effective in co...
متن کاملThe New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications
The administration of antiepileptic drugs (AEDs) is the first treatment of epilepsy, one of the most common neurological diseases. Therapeutic guidelines include newer AEDs as front-line drugs; monotherapy with new AEDs is delivered in Japan. While about 70% of patients obtain good seizure control by taking one to three AEDs, about 60% experience adverse effects and 33% have to change drugs. Co...
متن کاملNew drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...
متن کاملNEW DRUGS DRUG NEWS NEW DRUGS Cervical Cancer Vaccine
NEW DRUGS Cervical Cancer Vaccine The Food and Drug Administration (FDA) has approved Gardasil (Merck), the first vaccine developed to prevent cervical cancer, precancerous genital lesions, and genital warts caused by human papilloma virus (HPV) types 6, 11, 16, and 18 for females nine to 26 years of age. This agent was evaluated and approved in six months under the FDA’s priority review proces...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bosnian Journal of Basic Medical Sciences
سال: 2020
ISSN: 1840-4812,1512-8601
DOI: 10.17305/bjbms.2020.4908